Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News on Pharma

East Bristol has lost most pharmacies in England since 2016

And there are concerns that more pharmacies could close soon

Bristol Post

Climate change puts Lyme disease in focus for France's Valneva after COVID blow

With climate change spurring more cases of tick-borne Lyme disease, drugmaker Valneva is betting big on a vaccine as it looks beyond disappointing sales of its COVID shot.

Reuters

Another reason not to work in Indiana

Eli Lilly and Co. was quick to understand just how bad a near abortion ban can be on business.

Chicago Sun-Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Fears of 'chemist deserts' in areas where a third of pharmacies have shut in six years

New data reveals Bristol East, Bradford West, Pendle, Torbay and Hove are among the areas to have lost the largest numbers of pharmacies in the last few years

Daily Mirror

Amgen Aims To Stanch Generic Losses With $3.7 Billion ChemoCentryx Buyout

Amgen agreed to buy ChemoCentryx for $3.7 billion on Thursday, leading CCXI stock to rocket by a triple-digit percentage.

Investors Business Daily

Eli Lilly Slashes Profit Outlook After 'Significantly' Missing Second-Quarter Forecasts

Eli Lilly slashed its 2022 earnings outlook Thursday after "significantly" missing forecasts, leading LLY stock to crumble.

Investors Business Daily

COVID-19 vaccine sales push Moderna past expectations in Q2

Better-than-expected COVID-19 vaccine sales pushed Moderna past Wall Street’s second-quarter forecasts

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

AbbVie Leans On Immunology Drugs To Offset Aesthetic Downturn Amid Covid

AbbVie leaned heavily on immunology drugs in the second quarter, helping offset declines for key drugs. But AbbVie stock fell early Friday.

Investors Business Daily

Haleon’s debut suggests it may not be the jewel in GSK’s medicine cabinet

Consumer goods spin-off makes few waves in biggest European listing for more than a decade

The Guardian - UK

The Good News For Moderna's Covid Shot Wasn't Good News For Its Stock

Moderna stock fell Tuesday after the company said its omicron-targeting booster generated antibodies capable of tackling new variants.

Investors Business Daily

Africa CDC signs with Pfizer for COVID pill for African countries

Pfizer will now supply the COVID-19 pill that is highly effective in preventing hospitalisations and deaths.

Al Jazeera

US allows pharmacists to prescribe Pfizer's COVID pill

U.S. pharmacists can now prescribe the leading COVID-19 pill directly to patients

The Independent UK

Pfizer vaccines that target Omicron variant pass first step to approval in Australia

The TGA’s ‘provisional determination’ for two vaccines comes as BA.4 and BA.5 subvariants drive new wave of Covid cases

The Guardian - AU

Moderna confirms two-in-one Covid and flu jab in the works as testing under way

Scientists have developed an alternative to the current separate inoculations with the trial already under

Daily Record

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Alzheimer's Stocks Take A Body Blow After Roche's High-Profile Failure

A highly watched Alzheimer's drug from Roche failed in its final-stage test, but shares of Roche stock rose as others tumbled.

Reuters

Novartis drug combo shows promise in childhood brain cancer

An oral drug combination by Swiss pharmaceuticals company Novartis showed promise in treating a subgroup of patients suffering from a common childhood brain cancer in a trial.

Tribune News Service

Biotech buyout: San Diego's Turning Point Therapeutics sells to Bristol Myers Squibb for $4.1 billion

Bristol Myers Squibb has inked a deal to buy San Diego's Turning Point Therapeutics for $4.1 billion in cash, strengthening the pharmaceutical giant's presence in precision cancer treatments.

Investors Business Daily

GlaxoSmithKline Announces $3.3 Billion Buyout To Square Off With Pfizer, Merck

GlaxoSmithKline announced Tuesday a $3.3 billion deal to buy pneumonia vaccine-maker Affinivax. But GSK stock dipped at the close.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Tentative $161.5 million settlement reached in opioid trial

Attorneys for the state of West Virginia and two remaining pharmaceutical manufacturers have reached a tentative $161.5 million settlement

Benzinga

GlaxoSmithKline: Dividend Insights

Wednesday marks the last chance for investors to receive the next dividend payout from GlaxoSmithKline (NYSE:GSK).

StockNews.com

How Does the Pharmaceutical Industry Perform During Recessions?

The Fed’s aggressive interest rate hikes and high energy prices will likely fuel recessionary conditions. Moreover, the unexpected decline in GDP in the first quarter indicates a possible economic contraction. Amid such possibilities, the pharmaceutical industry could attract investors’ attention because of the inelastic demand for its products. Today, I…

Benzinga

AbbVie Walks Away From Parkinson's Drug Pact With BioArctic

AbbVie Inc (NYSE:ABBV) has ended a research partnership with Sweden's BioArctic, backing out further development of an experimental Parkinson's disease drug and other related medicines. A clinicaltrials.gov listing for ABBV-0805 says a Phase I study is "Withdrawn (Strategic considerations)." The partnership between AbbVie and BioArctic, which began in 2016, was focused on antibody drugs…

Benzinga

Cancer Drug Maker BeiGene Takes Action to Mitigate Delisting Risk

Key Takeaways: BeiGene has switched auditors for its New York listing to a U.S. company from a Chinese one in a move to comply with U.S. law The change could reduce the company’s threat of being forcibly delisted from the Nasdaq By Doug Young

Axios

Biden's looming prescription drug pricing dilemma

Pressure is increasing on the administration to go after drug patents.

Asharq Al-Awsat

New Cancer Immunotherapy Fails in First Roche Trial

A highly anticipated new cancer immunotherapy by Roche failed to slow the progression of an aggressive form of lung cancer, the Swiss drug maker said on Wednesday, boding ill for a range of rival drug developers working on similar compounds. The Skyscraper 2 trial was the first to produce results…

1 … 146 147 148 149

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.